Abstract:Background The most common type of kidney cancer that easily metastasizes is clear cell renal cell carcinoma (ccRCC). The expression levels of hyaluronan-mediated motility receptor (HMMR) in many tumor types are significantly enhanced. HMMR is closely associated with tumor-related progression, treatment resistance, and discouraging prognosis, has yet to be fully investigated in terms of its expression patterns and molecular mechanisms of action in ccRCC. Further research is imperative to elucidate these aspects. Methods We used The Cancer Genome Atlas (TCGA) database to preliminarily investigate HMMR expression and function in ccRCC. We assessed the differential expression level of HMMR between ccRCC cancerous tissues and their matched non-tumor tissues. Subsequently, a series of in vivo and in vitro experiments were designed to elucidate the biological function of HMMR in ccRCC, including Transwell migration assays, CCK-8 assays, clone formation assays and subcutaneous xenograft experiments in nude mice. Through bioinformatics analysis, we identified potential microRNAs (miRNAs) that may regulate HMMR, as well as the possible signaling pathways involved. Finally, we conducted a series of cellular functional experiments to validate our hypotheses regarding the HMMR axis. Results HMMR expression was observably up-regulated in tumor tissues of ccRCC patients, and elevated HMMR expression level showed a strong correlation with ccRCC progression and adverse prognoses of patients. Knocking down HMMR inhibited the proliferative and migratory abilities of ccRCC cells, while its overexpression amplified these oncogenic properties. In nude mouse model, reduced HMMR expression inhibited ccRCC tumor proliferation in vivo. Furthermore, overexpression of an upstream transcriptional regulator, miR-9-5p, effectively downregulated HMMR expression and thus impeded ccRCC cells proliferation and migration. In addition, HMMR might influence ccRCC growth via the Epithelial-Mesenchymal Transition (EMT) pathway and the Janus Kinase1/Signal Transducer and Activator of Transcription1 (JAK1/STAT1) pathway. Conclusions HMMR is overexpressed in ccRCC, and there is a significant link between high HMMR expression and tumor progression, as well as poor patient prognosis. Specifically, HMMR could be targeted and inhibited by miR-9-5p and might modulate the tumorigenesis and progression of ccRCC through both EMT and JAK1/STAT1 signaling pathway.

Hcrcn81 is Upregulated by Rapamycin Treatment in Human Colorectal Adenocarcinoma Cells

Up-regulated NRIP2 in Colorectal Cancer Initiating Cells Modulates the Wnt Pathway by Targeting RORβ.

Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines.

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Mir-9-5p/hmmr Regulates the Tumorigenesis and Progression of Clear Cell Renal Cell Carcinoma Through EMT and JAK1/STAT1 Signaling Pathway

Upregulation of Rab31 is associated with poor prognosis and promotes colorectal carcinoma proliferation via the mTOR/p70S6K/Cyclin D1 signalling pathway

CENPH Inhibits Rapamycin Sensitivity by Regulating GOLPH3-dependent mTOR Signaling Pathway in Colorectal Cancer.

Pathological Significance of Abnormal Recepteur D’origine Nantais and Programmed Death Ligand 1 Expression in Colorectal Cancer

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

The Role of C2orf68 and PI3K/Akt/mTOR Pathway in Human Colorectal Cancer

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

The Mechanistic Target of Rapamycin Complex 1 Pathway Contributes to the Anti-Tumor Effect of Granulocyte-Macrophage-Colony-Stimulating Factor-Producing T Helper Cells in Mouse Colorectal Cancer

Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506

Over-expressed RHEB promotes the progression of pancreatic adenocarcinoma

Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment

RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells

Rapamycin Alleviates 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis through Autophagy Induction and NF-κB Pathway Inhibition in Mice

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer

Rapamycin Induces Phenotypic Alterations in Oral Cancer Cells That May Facilitate Antitumor T Cell Responses

Activation of PI3K/AKT and MAPK Pathway Through a PDGFRβ-dependent Feedback Loop is Involved in Rapamycin Resistance in Hepatocellular Carcinoma.

Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma